Put companies on watchlist
Galenica AG
ISIN: CH0360674466
WKN: A2DN0K
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Galenica AG · ISIN: CH0360674466 · EQS - Company News (12 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1951159
22 July 2024 06:11PM

Galenica increases shareholding in Redcare Pharmacy to 10%


Galenica AG / Key word(s): Investment
Galenica increases shareholding in Redcare Pharmacy to 10%

22.07.2024 / 18:11 CET/CEST


Press release

Today, Galenica notified the Dutch Authority for the Financial Markets (AFM) of its 10% stake in Redcare Pharmacy N.V.

As part of the strategic partnership between Galenica and Redcare Pharmacy through the establishment of the joint venture Mediservice, Galenica has held a 7.9% stake in Redcare Pharmacy since May 2023. By increasing its participation, Galenica is strengthening its cooperation with Redcare Pharmacy, which has developed positively since the partnership was established. Galenica believes in the successful further development of Europe’s leading online pharmacy and intends to maintain its investment in Redcare Pharmacy in the long term. By increasing its stake to more than 10%, Galenica will be able to benefit from tax-free dividends and capital gains in the future. There are no plans to further increase the investment.

Dates for the diary

6 August 2024 Publication of Galenica Group half-year results 2024
24 October 2024 Galenica Group sales update
23 January 2025 Publication 2024 sales of the Galenica Group

 

For further information, please contact:

 

Media Relations:
E-Mail: media@galenica.com
Tel. +41 58 852 85 17
Investor Relations:
E-Mail: investors@galenica.com
Tel. +41 58 852 85 31

Welcome to the Galenica network!
Our ambition is to meet the needs of patients and customers in the Swiss healthcare market in a seamless, efficient and personalised way. To achieve this, we operate the Galenica network with over 20 Business Units, the strongest partners in the Swiss healthcare market. We offer fully integrated solutions both for customers and patients as well as for pharmacies, drugstores, medical practices, hospitals, retirement and nursing homes, home care providers, wholesalers, pharmaceutical companies, health insurance funds and other partners.
Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information concerning Galenica can be found at www.galenica.com.



End of Media Release


Language: English
Company: Galenica AG
Untermattweg 8
3027 Bern
Switzerland
Phone: +41 058 852 81 11
E-mail: info@galenica.com
Internet: https://www.galenica.com
ISIN: CH0360674466
Listed: SIX Swiss Exchange
EQS News ID: 1951159

 
End of News EQS News Service

1951159  22.07.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1951159&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Galenica AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.